Heesen P, Roos M
Contemp Clin Trials Commun. 2024; 39:101298.
PMID: 38689828
PMC: 11059437.
DOI: 10.1016/j.conctc.2024.101298.
Long B, Lai S, Wu J, Bellur S
Clin Pract. 2024; 14(1):69-88.
PMID: 38248431
PMC: 10801498.
DOI: 10.3390/clinpract14010007.
Allen A, Therneau T, Ahmed O, Gidener T, Mara K, Larson J
J Hepatol. 2022; 77(5):1237-1245.
PMID: 35843374
PMC: 9974107.
DOI: 10.1016/j.jhep.2022.07.004.
Halabi S, Lin C, Liu A
Stat Med. 2021; 40(12):2783-2799.
PMID: 33724513
PMC: 8113124.
DOI: 10.1002/sim.8928.
Spies R, Siegfried N, Myers B, Grobbelaar S
Trials. 2021; 22(1):189.
PMID: 33676535
PMC: 7936448.
DOI: 10.1186/s13063-021-05112-z.
Group sequential design for historical control trials using error spending functions.
Wu J, Li Y
J Biopharm Stat. 2019; 30(2):351-363.
PMID: 31718458
PMC: 7737423.
DOI: 10.1080/10543406.2019.1684305.
Milestone prediction for time-to-event endpoint monitoring in clinical trials.
Ou F, Heller M, Shi Q
Pharm Stat. 2019; 18(4):433-446.
PMID: 30806485
PMC: 6777948.
DOI: 10.1002/pst.1934.
Development of a genetic sensor that eliminates p53 deficient cells.
Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F
Nat Commun. 2017; 8(1):1463.
PMID: 29133879
PMC: 5684360.
DOI: 10.1038/s41467-017-01688-w.
Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.
Wu J, Xiong X
Stat Biopharm Res. 2017; 9(1):35-43.
PMID: 28966722
PMC: 5619877.
DOI: 10.1080/19466315.2016.1189355.
Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.
Wu J
Stat Biopharm Res. 2017; 9(1):25-34.
PMID: 28966721
PMC: 5619878.
DOI: 10.1080/19466315.2016.1174147.
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Antoniou M, Kolamunnage-Dona R, Jorgensen A
J Pers Med. 2017; 7(1).
PMID: 28125057
PMC: 5374391.
DOI: 10.3390/jpm7010001.
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.
Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman S
BMJ Open. 2016; 6(12):e011028.
PMID: 27932335
PMC: 5168661.
DOI: 10.1136/bmjopen-2016-011028.
A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225)....
Thomson C, Crane T, Miller A, Garcia D, Basen-Engquist K, Alberts D
Contemp Clin Trials. 2016; 49:181-9.
PMID: 27394382
PMC: 5108358.
DOI: 10.1016/j.cct.2016.07.005.
Survival trial design and monitoring using historical controls.
Wu J, Xiong X
Pharm Stat. 2016; 15(5):405-11.
PMID: 27307025
PMC: 5468795.
DOI: 10.1002/pst.1756.
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.
Xia F, George S, Wang X
Stat Biopharm Res. 2016; 8(1):12-21.
PMID: 27239255
PMC: 4879617.
DOI: 10.1080/19466315.2015.1093539.
Optimal two-stage log-rank test for randomized phase II clinical trials.
Kwak M, Jung S
J Biopharm Stat. 2016; 27(4):639-658.
PMID: 27050043
PMC: 5292306.
DOI: 10.1080/10543406.2016.1167073.
Work Engagement as a Predictor of Onset of Major Depressive Episode (MDE) among Workers, Independent of Psychological Distress: A 3-Year Prospective Cohort Study.
Imamura K, Kawakami N, Inoue A, Shimazu A, Tsutsumi A, Takahashi M
PLoS One. 2016; 11(2):e0148157.
PMID: 26841020
PMC: 4739688.
DOI: 10.1371/journal.pone.0148157.
Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen T
BMC Med Res Methodol. 2016; 16:12.
PMID: 26830911
PMC: 4736164.
DOI: 10.1186/s12874-016-0117-3.
Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
Polyak C, Yuhas K, Singa B, Khaemba M, Walson J, Richardson B
PLoS Med. 2016; 13(1):e1001934.
PMID: 26731191
PMC: 4701407.
DOI: 10.1371/journal.pmed.1001934.
Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat. 2015; 26(4):644-56.
PMID: 26098141
PMC: 5223772.
DOI: 10.1080/10543406.2015.1052494.
